1. Home
  2. NEGG vs DRUG Comparison

NEGG vs DRUG Comparison

Compare NEGG & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newegg Commerce Inc.

NEGG

Newegg Commerce Inc.

SELL

Current Price

$8.32

Market Cap

206.4M

ML Signal

SELL

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$21.20

Market Cap

228.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEGG
DRUG
Founded
2001
2019
Country
United States
United States
Employees
714
N/A
Industry
Other Specialty Stores
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
206.4M
228.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NEGG
DRUG
Price
$8.32
$21.20
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $107.47
AVG Volume (30 Days)
29.9K
★ 262.8K
Earning Date
08-27-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.69
$17.40
52 Week High
$80.00
$123.75

Technical Indicators

Market Signals
Indicator
NEGG
DRUG
Relative Strength Index (RSI) 31.67 28.22
Support Level N/A $17.40
Resistance Level $10.46 $56.79
Average True Range (ATR) 0.81 2.61
MACD 0.02 0.21
Stochastic Oscillator 7.69 41.35

Price Performance

Historical Comparison
NEGG
DRUG

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: